Publikationen, an denen er mitarbeitet Bruno Carlos Sangro Gómez-Acebo (31)

2023

  1. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

2022

  1. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

2019

  1. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know

    CardioVascular and Interventional Radiology, Vol. 42, Núm. 9, pp. 1262-1270

2017

  1. Conversion from calcineurin Inhibitor-Based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation

    Annals of Transplantation, Vol. 22, pp. 141-147

  2. Immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

    Immunotherapy of Hepatocellular Carcinoma (Springer International Publishing), pp. 51-68

  3. Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma

    RESISTANCE TO MOLECULAR THERAPIES FOR HEPATOCELLULAR CARCINOMA (SPRINGER INTERNATIONAL PUBLISHING AG), pp. 25-43

  4. NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma

    Oncotarget, Vol. 8, Núm. 25, pp. 40967-40981

  5. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

  3. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma

    Liver International, Vol. 35, Núm. 6, pp. 1715-1721

  4. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

    Liver International, Vol. 35, Núm. 5, pp. 1590-1596

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

  2. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension

    HPB, Vol. 16, Núm. 3, pp. 243-249

2013

  1. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma

    Journal of Hepatology, Vol. 59, Núm. 4, pp. 753-761

  2. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  3. Locoregional transarterial therapies for hepatocellular carcinoma: Transarterial chemoembolization and radioembolization

    Viszeralmedizin: Gastrointestinal Medicine and Surgery, Vol. 29, Núm. 2, pp. 92-102

  4. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087